The Cigna Group (CI) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

GuruFocus News
4 min read

In This Article:

  • Total Revenue: $63.7 billion for the third quarter.

  • Adjusted Earnings Per Share (EPS): $7.51 for the third quarter.

  • Shareholders' Net Income: $739 million or $2.63 per share for the third quarter.

  • Special Item Charges: $162 million or $0.58 per share after-tax net special item charges for the third quarter.

  • Evernorth Revenue: $52.5 billion for the third quarter.

  • Evernorth Pretax Adjusted Earnings: $1.9 billion, a 9% increase for the third quarter.

  • Specialty and Care Services Revenue: $23.8 billion for the third quarter.

  • Specialty and Care Services Adjusted Earnings: $825 million for the third quarter.

  • Cigna Healthcare Revenue: $13.3 billion for the third quarter.

  • Cigna Healthcare Pretax Adjusted Earnings: $1.2 billion for the third quarter.

  • Medical Care Ratio: 82.8% for the third quarter.

  • Share Repurchase: $5.7 billion year-to-date, including $715 million in October.

  • Full Year 2024 Adjusted EPS Outlook: At least $28.40, representing over 13% year-over-year growth.

Release Date: October 31, 2024

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

  • The Cigna Group (NYSE:CI) reported strong third-quarter financial results with total revenue of $63.7 billion and adjusted earnings per share of $7.51.

  • Evernorth Health Services, a growth platform of The Cigna Group (NYSE:CI), delivered strong top and bottom line contributions, driven by market-leading innovation and affordability initiatives.

  • The company is on track to deliver full-year adjusted earnings per share of at least $28.40 in 2024, representing more than 13% year-over-year growth.

  • The Cigna Group (NYSE:CI) has successfully expanded its biosimilar offerings, with significant adoption of HUMIRA biosimilars, contributing to cost savings for patients and clients.

  • The company has repurchased approximately $5.7 billion of its common stock year-to-date, demonstrating confidence in its business strength and sustainable growth.

Negative Points

  • The Cigna Group (NYSE:CI) recorded a noncash, after-tax net realized investment loss of $1 billion related to VillageMD, impacting shareholders' net income.

  • The company faces headwinds from lower net investment income due to the absence of the VillageMD dividend.

  • There is a potential for constrained overhead from the sale of the Medicare Advantage business, which the company will need to mitigate over time.

  • The Medicare Advantage market is currently challenged due to elevated medical costs and significant changes in star ratings, contributing to operational disruptions.

  • The company anticipates continued strategic investments across its portfolio, which may impact short-term financial performance.

Recommended Stories